Search for a trial

A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastasectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma

The main objective of the study is to determine time to progression of the primary malignancy (locally advanced or metastatic) in patients treated with ILuP and pulmonary metastasectomy. Secondary objectives are to assess pulmonary toxicity by…

The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.

Phase IThe primary aim of the phase I part of this study is to establish the safety profile and to determine the maximum tolerated dose of Re-188-HEDP combined with Capecitabine.Phase IIThe primary aim of the phase II part of this study is to obtain…

The Prostate CARE Study: Capecitabine (Xeloda??) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study.

The primary aim of the phase I part of this study is to establish the safety profile and to determine the maximum tolerated dose of capecitabine combined with Re-188-HEDP.The primary aim of the phase II part of this study is to obtain insight in the…

An open-label, multi-center, 2-arm PhaseI/II trial of LBY135 alone and in combination with capecitabine in advanced solid tumors

Primary:• Arm 1: To determine the maximum-tolerated dose (MTD) and doselimitingtoxicity (DLT) of single agent LBY135 and LBY135 when administered in combinationwith capecitabine to adult patients with advanced solid tumorsSecondary:• To characterize…

Predicting fracture risks in patients with metastatic bone defects: a multicenter prospective observational study. NWO STW Veni grant NPG.6778

-

Phase I dose-escalation trial for the combination of sorafenib with interleukin-2 (IL-2) in patients with clear cell renal cancer

Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…

Sentinel Node Biopsy in the Management of Oral and Oropharyngeal Squamous Cell Carcinoma

Evaluation and comparison of SNB and USgFNAC in the management of clinical negative neck in patients planned for transoral excision of oral and oropharyngeal squamous cell carcinoma.

Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases

Evaluation of tumor localization of In-111 labeled bevacizumab and possible correlation with VEGF expression in patients with colorectal liver metastases.